What is the difference between Cyltezo and Humira?
Medically reviewed by Judith Stewart, BPharm. Last updated on March 2, 2021.
Cyltezo (adalimumab-adbm) is a biosimilar to Humira (adalimumab), an anti-TNF-α monoclonal antibody used for the treatment of multiple conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.
A biosimilar is a product that is highly similar to an FDA-approved biologic, known as the reference product. Biosimilars have no clinically meaningful differences in safety, purity or potency compared to the reference product.
Cyltezo (adalimumab-adbm) was the second Humira (adalimumab) biosimilar approved by the FDA.
FDA approved biosimilars to Humira include:
- Amjevita (adalimumab-atto)
- Cyltezo (adalimumab-adbm)
- Hyrimoz (adalimumab-adaz)
- Hadlima (adalimumab-bwwd)
- Abrilada (adalimumab-afzb)
- Hulio (adalimumab-fkjp)
The approved indications for Humira and Cyltezo are not the same.
Like Humira, Cyltezo is used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.
Unlike Humira, Cyltezo is not approved for the treatment of hidradenitis suppurativa or uveitis.
Indications may also differ across population groups.
The following table compares the approved indications for Humira and Cyltezo:
|Rheumatoid Arthritis (RA)||adults||adults|
|Juvenile Idiopathic Arthritis (JIA)||
patients 2 years of age
patients 4 years of age
|Psoriatic Arthritis (PsA)||adults||adults|
|Ankylosing Spondylitis (AS)||adults||adults|
|Crohn’s Disease (CD)||patients 6 years of age and older||adults|
|Ulcerative Colitis (UC)||patients 5 years of age and older||adults|
|Plaque Psoriasis (Ps)||adults||adults|
|Hidradenitis Suppurativa (HS)||patients 12 years of age and older|
|Uveitis (UV)||patients 2 years of age and older|
Cyltezo is not an interchangeable product with Humira; the physician must write a prescription specifically for Cyltezo.
Cyltezo and Humira are both administered via subcutaneous injection.
- Cyltezo is available as a single-dose prefilled syringe.
- Humira is available as a single-dose prefilled pen, prefilled syringe, and single-dose vial.
- U.S. Food and Drug Administration. HUMIRA Product Label. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s417lbl.pdf [Accessed March 2, 2021]
- U.S. Food and Drug Administration. CYLTEZO Product Label. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761058s003lbl.pdf [Accessed March 2, 2021]
- U.S. Food and Drug Administration. What is a Biosimilar? Available at https://www.fda.gov/media/108905/download [Accessed March 2, 2021]
Related Medical Questions
- Does Humira cause weight gain or weight loss?
- What happens when you stop taking Humira?
- How long does it take for Humira to work?
- How much does Humira cost without insurance?
- How long can you stay on Humira?
- How long can Humira be out of the fridge?
- Can you drink alcohol while taking Humira?
- What are the new drugs for the treatment of rheumatoid arthritis (RA)?
- What are the new drugs for the treatment of plaque psoriasis?
- How many biosimilars have been approved in the United States?
- Can you take Humira with antibiotics?
- What is the difference between Amjevita and Humira?
Related Support Groups
- Humira (52 questions, 341 members)
- Adalimumab (8 questions, 10 members)
- Cyltezo (4 questions, 3 members)
- Rheumatoid Arthritis (233 questions, 1227 members)
- Ulcerative Colitis (29 questions, 171 members)
- Psoriatic Arthritis (27 questions, 246 members)
- Plaque Psoriasis (28 questions, 67 members)
- Crohn's Disease (26 questions, 269 members)
- Juvenile Idiopathic Arthritis (5 questions, 16 members)